Related Experiment Video
Updated: Sep 16, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Changes in the ocular surface and meibomian glands following administration of 0.01 and 0.02% atropine
Xueyan Li1, Yanying Zhu1, Haiyan Xie1
1The Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China.
Purpose:
To investigate the changes in the ocular surface and meibomian glands following the administration of 0.01 and 0.02% atropine.
Setting:
The Second Affiliated Hospital of Anhui Medical University, Anhui, China.
Methods:
In this randomized controlled study, the 0.01% group (18 patients, 36 eyes) and the 0.02% group (15 patients, 30 eyes) underwent assessments using the Ocular Surface Disease Index (OSDI), Visual Analogue scale (VAS), tear meniscus height (TMH), first noninvasive tear film breakup time (fNIBUT), and average noninvasive tear film breakup time (avNIBUT) at baseline (before administration) and at 1, 3, 6, and 12 months post-treatment. The meibomian glands of both the upper (U) and lower (L) eyelids were evaluated using Meibomian Gland Bio-image Analyzer, measuring parameters such as average gland diameter (avGD), average gland length (avGL), average gland area (avGA), deformation coefficient (DC), and gland visibility score (VS).
Results:
There were no statistically significant differences in any of the parameters within the 0.01% group (all p > 0.05). In the within-group comparisons of the 0.02% group, OSDI was higher at 3 month (p = 0.006) and was lower at 12 months (p = 0.038). VAS was higher at 3 months and 6 months (all p < 0.05). TMH was lower at 12 months (all p < 0.05). U-VS was lower at 3 months (p = 0.006) and higher at 6 and 12 months (all p < 0.05). L-avGL was higher at 1 month (p = 0.001) and lower at 6 months (p = 0.013). L-VS was higher at 6 and 12 months (all p < 0.05). In the 0.02% group, at 3 months, the change in U-VS and L-VS were positively correlated with the change in the VAS (r = 0.542, p = 0.037; r = 0.614, p = 0.015). At 6 months, the change in L-VS was positively correlated with the change in OSDI (r = 0.610, p = 0.016). At 12 months, the change in U-VS was positively correlated with the change in TMH (r = 0.521, p = 0.003).
Conclusion:
0.01% atropine had no significant impact. 0.02% atropine eye drops affected the lipid secretion of meibomian glands, tear meniscus height and subjective discomfort.
Related Concept Videos
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Cholinergic Antagonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Accessory Structures of the Eye

